Litcius/Paper detail

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Peter A. Fasching, Theresa Link, Jan Hauke, Fenja Seither, Christian Jackisch, Peter Klare, Sabine Schmatloch, Claus Hanusch, Jens Huober, Andrea Stefek, Sabine Seiler, Wolfgang Schmitt, Christoph Uleer, Gabriele Doering, Kerstin Rhiem, Andreas Schneeweiß, Knut Engels, Carsten Denkert, Rita K. Schmutzler, E. Hahnen, Michael Untch, Nicole Burchardi, Jens‐Uwe Blohmer, Sibylle Loibl

2020Annals of Oncology144 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOlaparibPaclitaxelBreast cancerHomologous recombinationOncologyInternal medicineHER2 negativeChemotherapyCancerMetastatic breast cancerGeneticsGenePolymerasePoly ADP ribose polymeraseBiologyPARP inhibition in cancer therapyBreast Cancer Treatment StudiesCancer Treatment and Pharmacology
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) | Litcius